BioMarin Pharmaceutical Inc.BMRNNASDAQ
Loading
BMRN Revenue Growth (YoY Quarterly)•+17.03%
Stock Alarm Pro
Growth Metrics
Latest: Q4 2025vs Q3 2025
Revenue GrowthGross Profit GrowthEBITDA GrowthOperating Income GrowthNet Income GrowthEPS GrowthEPS Diluted GrowthWeighted Average Shares GrowthWeighted Average Shares Diluted GrowthDividends per Share Growth
+17.03%
+13.0pp
-5.19%
-19.3pp
-102.01%
+1.3pp
-50.81%
+90.2pp
-137.28%
-8.3pp
-136.36%
-8.3pp
-134.38%
-5.3pp
+0.58%
-0.3pp
+0.41%
+3.0pp
+0.00%
+0.0pp
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +15.65% | +14.84% | +15.92% | +4.08% | +17.03% |
| Gross Profit Growth | +19.67% | +13.36% | +16.12% | +14.13% | -5.19% |
| EBITDA Growth | +278.19% | +92.77% | +96.77% | -103.36% | -102.01% |
| Operating Income Growth | +1035.15% | +153.10% | +129.87% | -141.00% | -50.81% |
| Net Income Growth | +513.22% | +109.43% | +124.43% | -128.98% | -137.28% |
| EPS Growth | +500.00% | +106.38% | +123.21% | -128.07% | -136.36% |
| EPS Diluted Growth | +481.82% | +106.52% | +123.64% | -129.09% | -134.38% |
| Weighted Average Shares Growth | +1.17% | +1.11% | +0.70% | +0.84% | +0.58% |
| Weighted Average Shares Diluted Growth | +2.47% | -1.40% | -1.93% | -2.59% | +0.41% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +575.42% | +271.28% | +56.00% | +66.46% | -46.32% |
| Free Cash Flow Growth | +0.00% | +1125.04% | +73.51% | +69.86% | -64.36% |
| Receivables Growth | +4.23% | +16.01% | +23.82% | +1.64% | +37.50% |
| Inventory Growth | +11.33% | +12.03% | +13.23% | +17.20% | +5.37% |
| Asset Growth | +2.15% | +3.99% | +5.51% | +11.15% | +8.66% |
| Book Value per Share Growth | +12.94% | +12.93% | +13.22% | +10.95% | +6.97% |
| Debt Growth | -45.00% | -45.10% | -45.09% | +0.26% | +6.66% |
| R&D Expense Growth | -15.87% | -22.57% | -12.23% | +121.46% | +10.90% |
| SG&A Expenses Growth | -3.05% | -8.76% | -11.67% | +5.88% | +200.87% |
1 / 4